摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(9CI)-1,2,3,4,6,7,8,10a-八氢嘧啶并[1,2-a]氮杂卓 | 484065-31-8

中文名称
(9CI)-1,2,3,4,6,7,8,10a-八氢嘧啶并[1,2-a]氮杂卓
中文别名
——
英文名称
1,8-diaza-bicyclo-[5.4.0]-undec-5-ene
英文别名
1,8-diazabicyclo[5.4.0]-undeca-5-ene;1,8-diazabicyclo-[5.4.0]-undec-5-ene;1,8-diazabicyclo[5,4,0]undec-5-ene;1,8-diazabicyclo[5.4.0]undec-5-ene;1,2,3,4,6,7,8,10A-octahydropyrimido[1,2-a]azepine
(9CI)-1,2,3,4,6,7,8,10a-八氢嘧啶并[1,2-a]氮杂卓化学式
CAS
484065-31-8
化学式
C9H16N2
mdl
——
分子量
152.239
InChiKey
BGNORAQHPDCDDJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    241.7±28.0 °C(Predicted)
  • 密度:
    1.02±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.1
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.78
  • 拓扑面积:
    15.3
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

点击查看最新优质反应信息

文献信息

  • Haloguanidine compounds, pharmaceutical compositions and methods of use
    申请人:ICI Americas Inc.
    公开号:US04362728A1
    公开(公告)日:1982-12-07
    Compounds useful for inhibiting gastric acid secretion and for the treatment of peptic ulcers caused or exacerbated by gastric acidity having the following formula (I): ##STR1## in which R.sup.1 and R.sup.2, are H, C.sub.1-10 alkyl, C.sub.3-8 cycloalkyl or cycloalkylalkyl in which the alkyl part is C.sub.1-6 and the cycloalkyl part is C.sub.3-8, each of the alkyl, cycloalkyl and cycloalkylalkyls being optionally substituted by one or more halogens selected from F, Cl and Br, provided that at least one of R.sup.1 and R.sup.2 is a halogen substituted alkyl, cycloalkyl or cycloalkylalkyl and provided that there is no halogen substituent on the carbon directly attached to the nitrogen; and X, m, Y, n and R.sup.3 are as described in the specification; and the pharmaceutically-acceptable acid-addition salts thereof. Processes for producing compounds of formula (I), pharmaceutical compositions containing them, methods of utilizing such compositions and intermediates useful for synthesizing compounds of formula (I) are also described.
    用于抑制胃酸分泌和治疗由胃酸引起或加重的消化性溃疡的化合物具有以下结构式(I):##STR1##其中R.sup.1和R.sup.2为H,C.sub.1-10烷基,C.sub.3-8环烷基或环烷基烷基,其中烷基部分为C.sub.1-6,环烷基部分为C.sub.3-8,每个烷基,环烷基和环烷基烷基可选择地被来自F、Cl和Br的一个或多个卤素取代,前提是R.sup.1和R.sup.2中至少有一个是卤素取代的烷基,环烷基或环烷基烷基,并且直接连接到氮的碳上没有卤素取代物;X,m,Y,n和R.sup.3如规范中所述;以及其药用可接受的酸加盐。还描述了制备结构式(I)化合物的方法,含有它们的药物组合物,利用这种组合物的方法以及用于合成结构式(I)化合物的中间体。
  • Process for producing stereoisomer of pyrrolidine derivative
    申请人:——
    公开号:US20030004208A1
    公开(公告)日:2003-01-02
    The present invention provides a process for producing optically active 3-hydroxy-4-methoxypyrrolidine, which is an intermediate for synthesizing a quinuclidine derivative useful as a squalene synthetase inhibitor, a salt thereof, or a hydrate thereof by subjecting a pyrrolidine derivative represented by the following formula (1-4): 1 wherein R 3a and R 3b are different and each of R 3a and R 3b represents a hydrogen atom or a methyl group, to optical division purification by using an optically active dibenzoyltartaric acid derivative or the like.
    本发明提供了一种用于生产光学活性的3-羟基-4-甲氧基吡咯烷的方法,这是一种合成作为角鲨烯合酶抑制剂有用的喹努啉衍生物的中间体,其盐类,或者其水合物,通过使用光学活性的二苯甲酰酒石酸衍生物等,对以下式子(1-4)所表示的吡咯烷衍生物进行光学分离纯化: 1 式中,R 3a 和R 3b 不同,R 3a 和R 3b 各自代表一个氢原子或甲基基团。
  • PYRROLIDINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME
    申请人:Eisai Co., Ltd.
    公开号:EP1375479A9
    公开(公告)日:2004-04-14
    A pyrrolidine derivative, which is an intermediate for a quinuclidine derivate side chain useful as a squalene synthase inhibitor, and producing method thereof are disclosed. A pyrrolidine derivative (X) represented by the following formula (X) (wherein R1 and R2 each represents a hydroxy group, C1-6 alkoxy groups or the like; R3 represents a hydrogen atom, a benzyl group or the like); or a salt thereof or a hydrate thereof:
    揭示了一种吡咯烷衍生物,它是喹诺啉衍生物侧链的中间体,可用作角鲨烯合酶抑制剂,并公开了其生产方法。 所述吡咯烷衍生物(X)由以下式(X)表示(其中R1和R2分别表示羟基,C1-6烷氧基或类似物;R3表示氢原子,苄基或类似物);或其盐或水合物:
  • PROCESS FOR PRODUCING INDOLOPYRROLOCARBAZOLE DERIVATIVE
    申请人:BANYU PHARMACEUTICAL CO., LTD.
    公开号:EP1541582A1
    公开(公告)日:2005-06-15
    The present invention provides a process for industrially advantageously producing a compound represented by the formula (I): or a pharmaceutically acceptable salt thereof, which is useful as an anticancer agent, and also provides a catalyst used for hydrogenation reaction in the process.
    本发明提供了一种工业上优势生产化合物的方法,该化合物由以下公式(I)表示:或其药学上可接受的盐,该化合物可用作抗癌剂,并且还提供了在该过程中用于氢化反应的催化剂。
  • Phosphonic acid derivatives and thionophosphonic acid derivatives
    申请人:Ciba-Geigy Corporation
    公开号:US05550276A1
    公开(公告)日:1996-08-27
    Compounds of the general formula I ##STR1## in which n is 1, 2 or 3 and in which X is oxygen or sulfur, T has the meaning of --S--, --S--S--, --S--S--, --S--S--S--S--, --S--S--S--S--S--, ##STR2## and Y has the meaning of ##STR3## in which Z has the meaning of --H, --COR.sup.13, --COOR.sup.13 or --CONHR.sup.13, and Q has the meaning of oxygen or --NR.sup.0 --, and R.sup.1, R.sup.2, R.sup.0, R.sup.4 and R.sup.13 are as defined in claim 1, with the proviso that the compound of the formula C.sub.2 H.sub.5 --S--CH.sub.2 CH(OH)--P(OC.sub.2 H.sub.5).sub.2 is excepted. The invention also relates to compositions containing the compounds of the formula I and organic materials, for example functional liquids and, in particular, lubricants.
    通式I的化合物##STR1##,其中n为1、2或3,X为氧或硫,T表示--S--,--S--S--,--S--S--,--S--S--S--S--,--S--S--S--S--S--,##STR2##,Y表示##STR3##,其中Z表示--H,--COR.sup.13,--COOR.sup.13或--CONHR.sup.13,Q表示氧或--NR.sup.0--,R.sup.1、R.sup.2、R.sup.0、R.sup.4和R.sup.13如权利要求1所定义,但公式C.sub.2 H.sub.5--S--CH.sub.2 CH(OH)--P(OC.sub.2 H.sub.5).sub.2的化合物除外。本发明还涉及包含通式I的化合物和有机材料的组合物,例如功能液体,特别是润滑剂。
查看更多

同类化合物

艾才派硕 甲基7-氮杂双环[4.1.0]庚-3-烯-7-羧酸酯 甲基2,5-二甲基-1H-氮杂卓-1-羧酸酯 氯化二氢1-[3-(3,5,7-三甲基-2-羰基-2,3--1H-吖庚英-1-基)丙基]哌啶正离子 氮杂环庚烷-2-酮肟 氮杂环丁烷并[1,2-a]噻吩并[2,3-c]吡咯 氮杂环丁烷并[1,2-a][1,3]二氧杂环戊并[4,5-c]吡咯 氮杂环丁烷并[1,2-a][1,2]恶唑并[3,4-d]氮杂卓 氮杂卓-2,7-二酮 替尼拉平 戊四唑 吖庚英并[2,1-a]异喹啉-5(4H)-硫酮,3-甲基- 他利克索 乙基7-氧代-6-氮杂双环[3.2.0]庚-3-烯-6-羧酸酯 [4-(4-甲基苯氧基)苯基]磺酰氯 N-叔丁基-6-甲氧基-5H-吡啶并[2,3-c]氮杂-9-胺 N-丁基-6-甲氧基-5H-吡啶并[2,3-c]氮杂-9-胺 N-Boc-2,3,4,5-四氢氮杂卓 N,N-二乙基-6-硝基-3H-氮杂-2-胺 N,N-二乙基-6-甲氧基-5H-吡啶并[2,3-c]氮杂-9-胺 DL-氨基己内酰胺 C-(6,7,8,9-四氢-5H-[1,2,4]噻唑并[4,3-a]-氮杂革-3-基)-甲基胺 9-氮杂双环[4.2.1]壬-2,4-二烯-9-甲醛 9-氮杂双环[4.2.1]壬-2,4-二烯 9-氮杂双环[4.2.1]壬-2,4,7-三烯-9-甲醛 9-氧杂-6-氮杂三环[4.3.1.03,8]癸-2,4,7-三烯 8-甲基-7H-吡啶并[1,2-a]氮杂-6-酮 7-氧代-6,7-二氢-1H-氮杂卓-4-羧酸 7-氧代-6,7-二氢-1H-氮杂卓-4-磺酰胺 7-乙基-9-甲基-6,7,8,9-四氢-5H-吡嗪并[2,3-d]氮杂卓-2-胺 7-(4-氟苯基)-3,4,5,6-四氢-2H-氮杂卓 6-甲氧基-N-丙基-5H-吡啶并[2,3-c]氮杂-9-胺 6-氮杂双环[3.2.1]辛-3-烯-7-酮 6-氮杂双环[3.2.1]辛-2-烯-7-酮 6-氧杂-4-氮杂三环[5.2.1.04,8]癸-1(9),2,7-三烯 6-BOC-2-溴-5,6,7,8-四氢-4H-噻唑并[4,5-D]吖庚因 6,7-二氮杂三环[5.4.1.01,5]十二碳-2,4,8,10-四烯 6,7-二氢-9-羟基-6-氧代-5H-吡啶并[3,2-b]氮杂卓-8-羧酸乙酯 6,7-二氢-5H-吡啶并[2,3-b]氮杂革-8(9H)-酮 6,7,8,9-四氢-5H-嘧啶并[4,5-d]氮杂卓 6,7,8,9-四氢-5H-咪唑并[1,2-a]氮杂卓-2-甲醛 6,7,8,9-四氢-5H-咪唑[1,2-a]氮杂卓 6,7,8,9-四氢-5H-吡啶并[3,4-c]氮杂卓 6,7,8,9-四氢-5H-吡啶并[3,2-B]氮杂 6,7,8,9-四氢-5H-吡啶并[2,3-d]吖庚因 6,7,8,9-四氢-5H-[1,2,4]噻唑并[4,3-a]氮杂卓-3-硫醇 6,7,8,9-四氢-2-(苯甲基)-5H-嘧啶并[4,5-d]氮杂卓 6,11-二氮杂三环[5.4.0.04,8]十一碳-1(11),4,7,9-四烯 5H-嘧啶并[4,5-d]氮杂卓 5H-嘧啶并[4,5-b]氮杂卓